Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.

André T, Berton D, Curigliano G, Sabatier R, Tinker AV, Oaknin A, Ellard S, de Braud F, Arkenau HT, Trigo J, Gravina A, Kristeleit R, Moreno V, Abdeddaim C, Vano YA, Samouëlian V, Miller R, Boni V, Torres AA, Gilbert L, Brown J, Dewal N, Dabrowski C, Antony G, Zografos E, Veneris J, Banerjee S

Open source

DOI: 10.1001/jamanetworkopen.2023.41165
Published: 2023 Nov 1
Container: JAMA network open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamanetworkopen.2023.41165,
  title = {Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.},
  author = {André T and Berton D and Curigliano G and Sabatier R and Tinker AV and Oaknin A and Ellard S and de Braud F and Arkenau HT and Trigo J and Gravina A and Kristeleit R and Moreno V and Abdeddaim C and Vano YA and Samouëlian V and Miller R and Boni V and Torres AA and Gilbert L and Brown J and Dewal N and Dabrowski C and Antony G and Zografos E and Veneris J and Banerjee S},
  year = {2023},
  journal = {JAMA network open},
  doi = {10.1001/jamanetworkopen.2023.41165},
  url = {https://doi.org/10.1001/jamanetworkopen.2023.41165}
}

RIS

TY  - JOUR
TI  - Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
AU  - André T
AU  - Berton D
AU  - Curigliano G
AU  - Sabatier R
AU  - Tinker AV
AU  - Oaknin A
AU  - Ellard S
AU  - de Braud F
AU  - Arkenau HT
AU  - Trigo J
AU  - Gravina A
AU  - Kristeleit R
AU  - Moreno V
AU  - Abdeddaim C
AU  - Vano YA
AU  - Samouëlian V
AU  - Miller R
AU  - Boni V
AU  - Torres AA
AU  - Gilbert L
AU  - Brown J
AU  - Dewal N
AU  - Dabrowski C
AU  - Antony G
AU  - Zografos E
AU  - Veneris J
AU  - Banerjee S
PY  - 2023
JO  - JAMA network open
DO  - 10.1001/jamanetworkopen.2023.41165
UR  - https://doi.org/10.1001/jamanetworkopen.2023.41165
ER  -

APA

T, A., D, B., G, C., R, S., AV, T., A, O., S, E., F, D. B., HT, A., J, T., A, G., R, K., V, M., C, A., YA, V., V, S., R, M., V, B., AA, T., L, G., J, B., N, D., C, D., G, A., E, Z., J, V., & S, B. (2023). Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2023.41165

Source records

pubmed · retrieved 2026-09-26T10:56:41.694Z